相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris
Giulio Fortuna et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2020)
Autoimmune mucocutaneous blistering diseases in the south of Italy: a 25-year retrospective study on 169 patients
Elena Calabria et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2020)
Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
Sara Cacciapuoti et al.
LIFE SCIENCES (2020)
Pemphigus vulgaris disease activity: The role of antibodies to desmogleins and their isotype
Sue-Ching Yeoh et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2019)
Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review
Soheil Tavakolpour et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center
Keshavamurthy Vinay et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Non-Desmoglein Antibodies in Patients with Pemphigus vulgaris
Kyle T. Amber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients
Aaron J. Robinson et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2018)
Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab
Lauren N. Albers et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Pascal Joly et al.
LANCET (2017)
Pemphigus
Michael Kasperkiewicz et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs
Bakr El-Zawahry et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2017)
Management of Pemphigus Vulgaris
Mimansa Cholera et al.
ADVANCES IN THERAPY (2016)
Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris
Rajsmita Bhattacharjee et al.
DERMATOLOGY (2016)
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Christoph T. Ellebrecht et al.
SCIENCE (2016)
First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus
Yung-Tsu Cho et al.
ACTA DERMATO-VENEREOLOGICA (2014)
Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms?
K. Sardana et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
The imbalance of Th17 and regulatory T cells in pemphigus patients
Ren-Chao Xu et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2013)
Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up
Giuseppe Cianchini et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Rituximab for the treatment of corticosteroid - refractory pemphigus vulgaris with oral and skin manifestations
Emma Craythorne et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2011)
Oropharyngeal Pemphigus Vulgaris and Clinical Remission A Long-Term, Longitudinal Study
Michele D. Mignogna et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2010)
Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases
M. D. Mignogna et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus
Misha Rosenbach et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
Dedee E. Murrell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity
M. Daneshpazhooh et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2007)
Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response
Ferdinand Breedveld et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy - A real clinical threat?
Michele D. Mignogna et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2007)
CD4(+)CD25(high) regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris
H. Sugiyama et al.
DERMATOLOGY (2007)
Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin
A. Razzaque Ahmed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-lasting remission of pemphigus vulgaris treated with rituximab
M Esposito et al.
ACTA DERMATO-VENEREOLOGICA (2006)
Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases
AR Ahmed et al.
ARCHIVES OF DERMATOLOGY (2003)
Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells
C Romano et al.
LEUKEMIA & LYMPHOMA (2003)
分享论文
